Actuate Therapeutics Inc (ACTU)
Actuate Therapeutics Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Fort Worth, TX, US. The stock last traded at $1.01, down 0.98% on the session, giving a market capitalisation of $24.2M. On trailing twelve-month figures it carries a trailing P/E of -1.02, a net margin of 0.0%. Its beta of 0.78 implies it has historically moved less than the broad market.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Actuate Therapeutics Inc is most often compared with the following Healthcare names: